TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Retinal Vein Occlusion

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Macular oedema due to retinal vein occlusion~Exclusion Criteria:~* Not living in metropolitan France

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ozurdex® (dexamethasone intravitreal implant) (Type: None): dexamethasone intravitreal implant 700 μg administered into the eye according to physician judgment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Kinesiotaping in Lateral Epicondylitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Having had symptoms less than 12 weeks~2. Tenderness and pain over lateral epicondylitis~3. Provocation of the lateral elbow pain with at least one of the following tests - resisted middle finger extension (Maudley's test), resisted wrist extension or passive stretch of wrist extensors (Mill's test).~Exclusion Criteria:~1. Cervical spondylosis or radiculopathy~2. Diabetes mellitus~3. Neuropathy~4. Arthritis in the upper extremities~5. History of injection and physical therapy for lateral epicondylitis within the last three months~6. Pregnancy~7. History of surgery or acute trauma in the elbow~8. Allergy to tape

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Kinesiotaping (Type: EXPERIMENTAL): Kinesio taping by using space correction and fascia correction techniques every 3 days for 2 weeks in addition to exercises
- Sham taping (Type: SHAM_COMPARATOR): Sham taping without using any techniques every 3 days for 2 weeks in addition to exercises
- Control (Type: OTHER): Stretching and strengthening exercises of wrist

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Tear Osmolarity \> 320 mOsm/L~* VAS eye dryness \> 40~* No other ocular pathology~* No contact lens wear~* Not currently on T cell modulator~* No change in therapy in last 2 months~* Willingness to adhere to therapy and study visits~* Patients qualified for prescription of lifitegrast drops~Exclusion Criteria:~* Contact lens use~* Eye surgery in Past 6 months~* Use of tear supplements in past 2 hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mild Dry Eye Cohort (Type: ACTIVE_COMPARATOR): Prospective 3 month study of subjects with Tear Osmolarity \>308 and VAS eye dryness ≥ 40 using 5% Lifitegrast ophthalmic solution BID.
- Moderate to Severe Dry Eye Cohort (Type: ACTIVE_COMPARATOR): Prospective 3 month study of subjects with Tear Osmolarity \>320 and VAS eye dryness ≥ 40 using 5% Lifitegrast ophthalmic solution BID.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Calcium Chloride for Prevention of Uterine Atony During Cesarean

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Pregnant female subjects at Lucile Packard Children's hospital / Stanford hospital undergoing Cesarean will be screened for inclusion in the study based upon presence of at least 2 risk factors for uterine atony/ postpartum hemorrhage. The risk factors include the following:~* intrapartum Cesarean delivery~* failed operative vaginal delivery with forceps or vacuum~* magnesium infusion~* chorioamnionitis~* multiple gestation~* polyhydramnios~* preterm delivery \<37 weeks~* prior history of postpartum hemorrhage~* labor induction or augmentation with oxytocin~* advanced maternal age~* obesity with body mass index \>40~Exclusion Criteria:~* a degree of case urgency to which taking time to consent for the study could compromise patient care, determined by anesthesiologist or obstetrician~* patient age \<18 years or \>50 years~* renal dysfunction with serum Creatinine \> 1.0~* abnormal cardiac function or history of arrhythmia~* patient taking digoxin~* patient currently taking a calcium channel blocker for a cardiovascular indication

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Calcium Chloride (Type: EXPERIMENTAL): Non-participating anesthesiologist prepares the drug solution, which is 1 gram of calcium chloride diluted into a total volume of 60 milliliters normal saline, labeled only with the study ID number. The solution is administered intravenously utilizing an Alaris syringe pump and microbore tubing, with infusion starting immediately at the time of fetal delivery at a rate of 360 milliliters per hour (for a calcium infusion rate of 100 milligrams /minute until the full 1 gram dose is administered).~This is a one-time administration. Patients continue to receive all standard care during the Cesarean including 1 unit oxytocin bolus at the time of fetal delivery + continuous oxytocin infusion at 7.5 units per hour per our institution's protocol.
- Placebo (Type: PLACEBO_COMPARATOR): Non-participating anesthesiologist prepares the placebo solution, which is 60 milliliters normal saline, labeled only with the study ID number. The solution is administered intravenously utilizing an Alaris syringe pump and microbore tubing, with infusion starting immediately at the time of fetal delivery at a rate of 360 milliliters per hour.~This is a one-time administration. Patients continue to receive all standard care during the Cesarean including 1 unit oxytocin bolus at the time of fetal delivery + continuous oxytocin infusion at 7.5 units per hour per our institution's protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Effectiveness of Methylphenidate in Swedish Male Prison Inmates With Attention-deficit Hyperactivity Disorder (ADHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male, 18-65 years, imprisoned at Norrtalje Prison~* WURS-score of 36 or more and fulfilling at least 4 out of 6 criteria on ASRS Screener in an initial screening preceding the trial~* Can read and understand Swedish well enough to participate in the evaluation preceding the trial~* Diagnosis of ADHD according to the Diagnostic and Statistical Manual of Mental Diseases, Fourth Edition, (DSM-IV) and confirmed by the neuropsychiatric assessment including structured diagnostic interviews and neuropsychological measurements.~* At least 14 months left to conditional release.~* Informed Consent Form to participate in the study signed by the subject.~* Subject agrees to take only the supplied study drug as treatment for ADHD during the study~* Subject is able to comply with the study visit schedule and willing and able to complete the protocol-specified assessments.~* Healthy on the basis of a physical examination and the results of blood biochemistry tests. If the results of the biochemistry tests are not within the normal reference ranges, the subject may be included if the investigator considers the deviations are not clinically relevant.~Exclusion Criteria:~* Known to be a non-responder to methylphenidate.~* Known allergy or hypersensitivity to methylphenidate.~* Any clinically unstable psychiatric condition including, but not limited to, acute mood disorder, bipolar disorder, acute OCD.~* A diagnosis of substance use disorder (abuse/dependence) according to DSM-IV criteria within 3 months prior to screening evaluation for the study.~* Known mental retardation.~* Subjects with history of epileptic seizures, glaucoma, uncontrolled hypertension, angina pectoris, cardiac arrhythmias or structural heart abnormalities.~* Use of monoamine oxidase inhibitors, fluoxetine, venlafaxine, reboxetine, duloxetine.~* Use of alpha-2-receptor agonists, neuroleptics, theophylline, coumarin anticoagulants or anticonvulsants.~* Liver or renal insufficiency. Subjects with hepatitis C without liver insufficiency don´t have to be excluded as long as liver enzymes are followed through the study.~* Subjects who are suicidal.~* Lactose intolerance.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Methylphenidate (Type: EXPERIMENTAL): PR OROS Methylphenidate given orally once daily for 5 weeks. The dosage was as follows: 36 mg per day from day 1-3, 54 mg per day from day 4-7 and 72 mg per day from day 8 until end of 5th week.
- Sugar pill (Type: PLACEBO_COMPARATOR): Placebo given orally once daily for 5 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients may be included in the study if they meet all of the following criteria:~* Male or non-pregnant female at least 18 years of age~* Patients undergoing percutaneous coronary intervention (PCI):~  1. Stable angina (SA) patients with diagnostic coronary angiography within 90 days prior to randomization demonstrating atherosclerosis~ 2. Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) patients with diagnostic coronary angiography within 72 hours prior to randomization demonstrating atherosclerosis~ 3. ST-segment elevation myocardial infarction (STEMI) patients (diagnostic angiography not required)~* Provide written informed consent~Exclusion Criteria:~Patients will be excluded from the study if any of the following exclusion criteria apply prior to randomization:~* Receipt of any P2Y12 inhibitor at any time in the 7 days preceding randomization~* Eptifibatide and tirofiban usage within 12 hours preceding randomization (most recent dose must have been administered ≥12 hours prior to randomization)~* Abciximab usage within 7 days preceding randomization~* Receipt of fibrinolytic therapy in the 12 hours preceding randomization~* Increased bleeding risk: ischemic stroke within the last year or any previous hemorrhagic stroke; tumor, cerebral arteriovenous malformation, or intracranial aneurysm; recent (\<1 month) trauma or major surgery (including bypass surgery); currently receiving warfarin; active bleeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cangrelor (Type: EXPERIMENTAL): Cangrelor was administered as a 30 µg/kg bolus followed by a 4.0 µg/kg/min cangrelor IV infusion for a minimum of 2 hours or until conclusion of the index procedure, whichever is longer. At the discretion of the treating physician, the infusion could be continued for a total duration of 4 hours.~Following the discontinuation of the cangrelor infusion, 600mg of clopidogrel was administered.
- clopidogrel (Type: ACTIVE_COMPARATOR): Clopidogrel 300 mg or 600 mg administered pre or post PCI. Selection of dose and timing of dose were per investigator discretion.~During the PCI a placebo infusion was given to maintain the blinding of the trial. In addition, placebo capsules were administered at the end of the infusion mimic the 600mg post infusion dose provided in the cangrelor arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Study of Minocycline for Negative and Cognitive Symptoms in Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male and female,were aged 18-40 years~* were currently diagnosed with DSM-IV schizophrenia~* were able to comprehend the cognition test~* patients or guardian signed informed consent,were able to comprehend the procedure and aims of the study,agreed to join the study~* patient's current antipsychotic medication regimen must be stable~* must be in a stable living arrangement~Exclusion Criteria:~* had ever been hypersensitivity to minocycline or tetracycline;~* had acute,unstable,significant,or untreated medical illness besides schizophrenia~* were pregnant or breast-feeding;~* had a DSM-IV diagnosis of substance abuse or dependency;~* had a tendency to suicide or Violence,self-harm;~* had taken immunosuppressive agents in the preceding 3 months before study entry;~* had influenza or fever in the preceding 2 weeks before study entry;~* had a DSM-IV diagnosis of emotional psychosis,Mental retardation,etc.~* has suicidal attempts or ideation or violent behavior within the last 12 months~* patient has mental retardation or severe organic brain syndromes~* treatment with Electroconvulsive Therapy (ECT) within 6 months prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): Subjects will be given with 200mg/day placebo(100mg,bid) and variable dose SGA. All drugs will be administered orally.
- minocycline (Type: ACTIVE_COMPARATOR): Subjects will be given with 200mg/day minocycline (100mg,bid)and variable dose SGA.All drugs will be administered orally.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~Patients with CVID (Common Variable Immunodeficiency) or XLA (X-linked agammaglobulinemia) who:~Participated in the Phase III clinical study with intravenous IgPro10 (study number ZLB03_002CR) at 3- or 4- weekly intervals for 12 months (referred to as 'old' subjects)~OR~Were ≥ 6 years of age, were on other stable intravenous immunoglobulin therapy (200-800 mg IgG per kg body weight) at 3- or 4-week intervals for at least 6 months, AND were interested in participating in the Phase III clinical study with subcutaneous IgPro20 (study number ZLB04_009CR) (referred to as 'new' subjects)~Written informed consent~Key Exclusion Criteria:~Diagnosis of epilepsia~Insulin dependent diabetes~Administration of steroids (daily ≥ 0.15 mg prednisone equivalent/kg/day) or other immunosuppressive drugs~History of cardiac insufficiency (NYHA III/IV), cardiomyopathy, congestive heart failure, severe hypertension

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 71 Years
- Healthy Volunteers: f

Study Arms:
- IgPro10 (Type: EXPERIMENTAL): See Intervention Description

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: GORE EXCLUDER® Endoprosthesis - Low Permeability in Treatment of Abdominal Aortic Aneurysms

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Infrarenal Abdominal Aortic Aneurysms less than 4.5 cm in diameter~2. Anatomy meets EXCLUDER Bifurcated Endoprosthesis - Low Permeability specification criteria per Instructions for Use~3. Access vessel able to receive 18 French introducer sheath~4. Life expectancy \> 2 years~5. Appropriate candidate for endovascular repair~6. Ability to comply with protocol requirements including follow-up~7. 21 years of age or older, male or infertile female\*\*~Exclusion Criteria:~1. Mycotic or ruptured aneurysm~2. Participating in another investigational device or drug study within one year~3. Documented history of drug abuse within six months~4. Myocardial infarction or cerebral vascular accident within six weeks~5. Pulmonary insufficiency requiring chronic home oxygen or inability to ambulate due to pulmonary function~6. Iliac anatomy that would require occlusion of both internal iliac arteries~7. Planned occlusion or reimplantation of significant mesenteric or renal arteries~8. Planned concomitant surgical procedure or previous major surgery within 30 days~9. Previous prosthesis placement in the aorta or iliac arteries~10. Degenerative connective tissue disease (e.g., Marfan's and Ehlers Danlos Syndrome)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single Tablet Regimen (STR) Simplification Study for HIV-1 Infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 positive patients who have maintained an HIV-1 viral load \<200 copies/mL, for at least 3 months.~* Patients must be on their first HAART or have documented viral suppression on a PI-based regimen at the time of any prior change in therapy.~* HAART must consist of either:~  1. A PI (with or without ritonavir) + at least 2 NRTIs or~ 2. An NNRTI + at least 2 NRTIs.~* Negative serum pregnancy test.~Exclusion Criteria:~* Patients who have taken any NNRTI prior to their current therapy.~* Patients who have taken a NRTI-only therapy for greater than 7 days prior to their current therapy.~* Patients who are currently taking EFV+FTC+TDF.~* Patients who have a creatinine clearance of \<60 mL/min by Cockcroft-Gault estimation.~* Patients who have experienced virologic failure with any previous ARV therapy.~* Patients who have documented resistance to any of the study agents at any time in the past.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Staphylococcus Aureus Colonization in Hand Eczema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects at least 18 years of age with a clear diagnosis of moderate-to-severe hand or hand/foot dermatitis.~* Subjects must be in general good health as confirmed by a medical history.~* Subjects must be capable of understanding and willing to provide a signed and dated written voluntary informed consent before any protocol specific procedures are performed.~* At the Baseline Visit, Subjects must have a Physician's Global Assessment (PGA) of at least 3 (moderate severity).~* Subject must be willing and able to participate in the study as an outpatient, making frequent visits to the study center during the treatment and follow-up period periods and comply with all study requirements.~* If a subject is a female of childbearing potential she must have a negative urine pregnancy test prior to study treatment initiation and must agree to use an approved method of birth control during the study period (barrier, oral, injection, intrauterine). NOTE: Post-menopausal (amenorrhea for at least one year) or surgically sterile (tubal ligation and/or hysterectomy) females are categorized as non-childbearing potential.~Exclusion Criteria:~* Non-English speaking subjects~* Females who are pregnant, breast feeding, or attempting to conceive.~* Subjects with a history of known or suspected intolerance to any of the excipients of retapamulin 1% ointment or clobetasol propionate 0.05% foam.~* Subjects who have used any topical corticosteroids, topical antibiotics, topical immunosuppressants, other topical therapies (tar, calcineurin inhibitors), or phototherapy (PUVA, UVB) within eight weeks of the Baseline Visit.~* Subjects who have used any systemic corticosteroids, systemic antibiotics, or systemic immunosuppressants therapies within eight weeks of the Baseline Visit.~* Subjects with any overt signs of skin atrophy, telangiectasias, and/or striae in the target area(s).~* Subjects with any active skin malignancy.~* Subjects requiring the use of medications known to alter the course of atopic dermatitis during the study period.~* Subjects who are currently participating in or, within the previous 28 days, have participated in another study for the treatment for atopic dermatitis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Retapamulin 1% ointment (Type: ACTIVE_COMPARATOR): Retapamulin 1% ointment for 5 days AND clobetasol propionate foam for 14 days
- Placebo ointment (Type: PLACEBO_COMPARATOR): Placebo ointment for 5 days AND clobetasol propionate foam for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete